Alvine Hopes To Bring The First Celiac Drug To Market With New Partner AbbVie
This article was originally published in The Pink Sheet Daily
Alvine and AbbVie have inked a deal that could allow the larger company to acquire the biotech based on results of a Phase IIb trial for its celiac disease treatment.
You may also be interested in...
Abbott’s proprietary pharmaceutical business will officially begin business as a separate entity called AbbVie Jan. 1, but a key pipeline opportunity – bardoxolone – is in doubt after a Phase III trial was terminated due to safety.
Alvine Pharmaceuticals aims to treat celiac disease-a common hereditary autoimmune disorder in which the intestinal lining reacts to wheat, barley or rye gluten, leading to pain, bloating, and damage to the gut--with an orally available drug meant to degrade gluten in the stomach into peptide fragments too small to stimulate an immune response. Generally, antigens need to be at least nine amino acids long to rouse an immune response, but Alvine expects its lead compound to chop up gluten into peptide fragments a third that size or smaller.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.